AnaptysBio is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes rosnilimab (pathogenic T cell depleter for rheumatoid arthritis), ANB033 (CD122 antagonist for celiac disease and eosinophilic esophagitis), and ANB101 (BDCA2 modulator). The company also out-licensed dostarlimab (Jemperli) to GSK and imsidolimab to Vanda Pharmaceuticals, generating milestone and royalty revenue.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-088290 | EDGAR | 80K words |
| 2025-02-27 | 2024-12-31 | 0001370053-25-000024 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0001370053-24-000011 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001370053-23-000020 | EDGAR | — |
| 2022-03-07 | 2021-12-31 | 0001370053-22-000009 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001370053-21-000019 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001370053-20-000009 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001370053-19-000006 | EDGAR | — |
| 2018-03-05 | 2017-12-31 | 0001370053-18-000014 | EDGAR | — |
| 2017-03-08 | 2016-12-31 | 0001564590-17-003710 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001370053-25-000089 | EDGAR | 47K words |
| 2025-08-06 | 2025-06-30 | 0001370053-25-000064 | EDGAR | — |
| 2025-05-05 | 2025-03-31 | 0001370053-25-000046 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001370053-24-000054 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001370053-24-000041 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001370053-24-000027 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001370053-23-000065 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001370053-23-000049 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001370053-23-000040 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001370053-22-000066 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001370053-22-000043 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0001370053-22-000032 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001193125-26-127783 | EDGAR | 22K words |
| 2026-03-03 | 0001193125-26-088239 | EDGAR | — |
| 2026-01-09 | 0001370053-26-000002 | EDGAR | — |
| 2025-11-26 | 0001370053-25-000103 | EDGAR | — |
| 2025-11-21 | 0001370053-25-000097 | EDGAR | — |
| 2025-11-21 | 0001370053-25-000096 | EDGAR | — |
| 2025-11-10 | 0001370053-25-000091 | EDGAR | — |
| 2025-11-04 | 0001370053-25-000088 | EDGAR | — |
| 2025-10-14 | 0001370053-25-000083 | EDGAR | — |
| 2025-09-29 | 0001370053-25-000081 | EDGAR | — |
171 total filings indexed. 139 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001370053 |
| Ticker | ANAB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.anaptysbio.com |
| Listed | 2017-01-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report